Interestingly, this group screened 132 repurposed drugs, including 67 neuroactive agents (NADs) and 65 oncology drugs, using ex vivo tumor culture and identified Rimonabant, a CB1R antagonist, as a top‐ranked NAD (rank 6) for cytotoxicity of GBM. Here, CNR1 is linked to neoplasm.